BRAF and non-small cell lung carcinoma: In conclusion, the activation of wild-type EGFR may play a significant role in BRAF class 3–mutated NSCLC, which currently represents a population orphan of targeted therapies, suggesting that these tumors might be responsive to EGFR-TKIs.